Basic information Safety Supplier Related

S-(-)-Carbidopa

Basic information Safety Supplier Related

S-(-)-Carbidopa Basic information

Product Name:
S-(-)-Carbidopa
Synonyms:
  • mk486
  • 4-dihydroxy-alpha-methyl-alpha-hydrazino-(s)-benzenepropanoicaci
  • 4-dihydroxy-alpha-methyl-alpha-hydrazino-l-hydrocinnamicaci
  • alpha-methyldopahydrazine
  • -Hydrazino-3,4-dihydroxy-methylbenzenep-ropanicacid
  • -Hydrazino-3,4-dihydroxy-methylhy-drocinnamicacid
  • hydrazino-alpha-methyldopa
  • l-alpha-methyldopahydrazine
CAS:
28860-95-9
MF:
C10H14N2O4
MW:
226.23
EINECS:
657-445-4
Product Categories:
  • API
  • Lodosyn
  • L-Aromatic Amino Acid Decarboxylase
Mol File:
28860-95-9.mol
More
Less

S-(-)-Carbidopa Chemical Properties

Melting point:
203-205° (dec); mp 208°
alpha 
D -17.3° (methanol)
Boiling point:
367.84°C (rough estimate)
Density 
1.2616 (rough estimate)
refractive index 
1.5000 (estimate)
storage temp. 
-20°C
solubility 
DMSO (Slightly), Methanol (Slightly)
pka
3.40±0.14(Predicted)
form 
powder
color 
White to Off-White
Stability:
Unstable in Solution
CAS DataBase Reference
28860-95-9(CAS DataBase Reference)
More
Less

Safety Information

WGK Germany 
3
RTECS 
MW5298000

MSDS

More
Less

S-(-)-Carbidopa Usage And Synthesis

Chemical Properties

White Solid

Originator

Sinemet,Merck Sharp and Dohme,Italy,1974

Uses

in combinaison with levodopa as antiparkinsonian;inhibits aromatic-L-amino-acid decarboxylase (DOPA Decarboxylase or DDC)

Uses

(S)-(-)-Carbidopa is a peripheral decarboxylase inhibitor that is commonly used in combination with L-DOPA (D533751) for treatment of Parkinsonism. S(-)-Carbidopa ( has also been shown to prolong the elimination half-life of L-DOPA from blood plasma and skeletal muscle.

Definition

ChEBI: 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversi n of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.

Manufacturing Process

To a solution of vanillin in toluene is added nitroethane, butylamine and glacial acetic acid. The mixture is refluxed and the water of reaction is steadily azeotropically removed by distillation. After the theoretical amount of water is distilled out, distillation is continued to remove excess reactants. The last trace of excess reactants is then removed at room temperature under a vacuum. The product is then triturated with a hydrocarbon solvent such as Skellysolve B and is thus obtained in a crystalline state. In general, however, it is preferred to dissolve the residue directly in toluene for use in the next step, without isolating the 1-(2-nitropropen-1-yl)-4-hydroxy-3- methoxybenzene.
A mixture of iron, ferric chloride and water is added to the toluene solution. The mixture is heated to reflux and concentrated hydrochloric acid is added dropwise at a rate calculated to keep the mixture refluxing vigorously. After the hydrochloric acid is all added, the refluxing is continued by the application of heat for several hours. A siliceous filter aid is then added to the cooled reaction mixture and the material is removed by filtration. The filter cake is washed four times, each time with 90 ml of benzene. The organic layer is then separated from the filtrate. The water layer is acidified to a pH of 2 and extracted three times with 90 ml portions of benzene.
These extracts are then combined with the organic solvent layer and the combined organic phase is extracted four times with 100 ml portions of water. It is then stirred for an hour with 230 ml of 10% sodium bisulfite solution. The organic solvent phase is then separated, washed seven times with 100 ml portions of water and dried over magnesium sulfate. Evaporation of the solvent gives 1-(4-hydroxy-3-methoxyphenyl)-2-propanone in the form of an oil.
A mixture of 59.5 g of that oily product, 1.85 liters of benzene and 1 kg of potassium bisulfite in 200 liters of water is stirred at room temperature for two hours. The precipitated bisulfite addition product of the ketone is isolated by filtration and washed with isopropanol and then with ether. Five hundred grams of the adduct is mixed with 119.5 g of potassium cyanide, 292 ml of 85% hydrazine hydrate and 910 ml of water. The mixture is stirred overnight at room temperature after which the product is isolated by filtration. The product is washed 3 times with 250 ml portions of water and then 3 times with 230 ml portions of ether. It is then air dried and vacuum dried at room temperature.
Fifty cubic centimeters of concentrated hydrochloric acid is saturated with hydrogen chloride gas at -10°C. To the solution is then added 2.5 g of the intermediate product, of the formula shown above, slowly with vigorous stirring. The mixture is allowed to stir overnight while warming at room temperature gradually. It is then concentrated in vacuo to a syrup. To the residual syrup is added 100 ml of 48% hydrobromic acid. The reaction vessel is purged with nitrogen and the reaction mixture is then refluxed for 3 hours after which it is concentrated in vacuo to a mixture of a syrup and a solid. The residue is taken up in sufficient water to form a clear solution. Activated charcoal is added and the mixture is heated to boiling and filtered.
The filtrate is concentrated to dryness in vacuo and the residue is taken up in 25 cc of ethanol. The residual ammonium bromide is removed by filtration and to the filtrate there is added sufficient diethylamine to change the pH to 6.4. The mixture is warmed to 60°C and then cooled to room temperature. It is then allowed to stand overnight to effect complete crystallization. It is then cooled to 0°C and the product is isolated by filtration, washed with methanol and air dried. The product (α-hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)- propionic acid) is recrystallized once from water using a proportion of 15 cc water per gram of product.

brand name

Lodosyn (Bristol-Myers Squibb).

Therapeutic Function

Muscle relaxant, Antiparkinsonian

General Description

Carbidopa is used for treating restless legs (RL) syndrome and periodic leg movements in sleep (PLMS). Carbidopa along with levodopa is used to treat Parkinson′s disease.

Biological Activity

Peripheral decarboxylase inhibitor, used in combination with levodopa for treatment of Parkinsonism.

Biochem/physiol Actions

Peripheral inhibitor of L-aromatic amino acid decarboxylase. When co-administered with L-DOPA, it prevents extra-CNS conversion to dopamine, thereby increasing CNS concentrations of effective compounds. Selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells by increasing H2O2 in these cell lines, which are sensitive to reactive oxygen species.

storage

Store at RT

S-(-)-CarbidopaSupplier

Zhejiang Yefeng Pharmaceutical Co., Ltd. Gold
Tel
86-579-86733319
Email
sales@wildwindchem.com
Shanghai Boyle Chemical Co., Ltd.
Tel
021-50182298 021-50180596
Email
sales@boylechem.com
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
INTATRADE GmbH
Tel
+49 3493/605464
Email
sales@intatrade.de
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com